Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption

Gianpiero D'Offizi, Carla Montesano, Chiara Agrati, Cristiana Gioia, Massimo Amicosante, Simone Topino, Pasquale Narciso, Leopoldo Paolo Pucillo, Giuseppe Ippolito, Fabrizio Poccia

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective: The influence of structured treatment interruption on effector/memory CD8 T cell dynamics was analysed in chronic HIV-infected patients showing a rapid or delayed viral rebound. Design: Structured treatment interruption consisted of at least one month of discontinuation, followed by highly active antiretroviral therapy (HAART) resumption. Two groups of HIV structured treatment interruption patients were selected on the basis of plasma viral HIV-RNA value (> 30 000 copies/ml, branched DNA): group A (n = 14), patients with a rapid viral rebound (within one month) and group B (n = 6), patients with a delayed or no viral rebound (after a minimum of 4 months). Methods: A clinical and immunological follow-up was performed at HAART suspension (t 0), one month from suspension (t 1), at HAART resumption (t 2), and 30 days from resumption (t 3). Results: A sustained viral rebound was observed in group A patients, showing a rapid expansion of circulating CD8 T lymphocytes. In this group, the frequencies of CD8 T cells releasing IFN-γ after mitogen-induced or Gag-specific stimulation were highly increased after HAART discontinuation. Nevertheless, these CD8 T lymphocytes were mainly composed of pre-terminally differentiated cytotoxic T lymphocytes (CTL) expressing a CCR7- CD27+/- CD45RA- phenotype and a reduced amount of perforin. In contrast, group B patients showed no significant changes in immunological parameters during a prolonged drug-free period. Conclusion: These data indicate that monitoring CD8 T cell dynamics during structured treatment interruption could be clinically relevant, and new therapeutic strategies should aim qualitatively to restore CTL effector functions.

Original languageEnglish
Pages (from-to)2431-2438
Number of pages8
JournalAIDS (London, England)
Volume16
Issue number18
DOIs
Publication statusPublished - Dec 6 2002

Fingerprint

Highly Active Antiretroviral Therapy
HIV
T-Lymphocytes
Cytotoxic T-Lymphocytes
Suspensions
Therapeutics
Perforin
Viral RNA
Mitogens
Phenotype
DNA
Pharmaceutical Preparations

Keywords

  • CCR7
  • CD27
  • CTL
  • HAART
  • HIV-1 Gag
  • Peptides

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. / D'Offizi, Gianpiero; Montesano, Carla; Agrati, Chiara; Gioia, Cristiana; Amicosante, Massimo; Topino, Simone; Narciso, Pasquale; Pucillo, Leopoldo Paolo; Ippolito, Giuseppe; Poccia, Fabrizio.

In: AIDS (London, England), Vol. 16, No. 18, 06.12.2002, p. 2431-2438.

Research output: Contribution to journalArticle

D'Offizi, Gianpiero ; Montesano, Carla ; Agrati, Chiara ; Gioia, Cristiana ; Amicosante, Massimo ; Topino, Simone ; Narciso, Pasquale ; Pucillo, Leopoldo Paolo ; Ippolito, Giuseppe ; Poccia, Fabrizio. / Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. In: AIDS (London, England). 2002 ; Vol. 16, No. 18. pp. 2431-2438.
@article{61f3443e0af04545b0d882129786b10d,
title = "Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption",
abstract = "Objective: The influence of structured treatment interruption on effector/memory CD8 T cell dynamics was analysed in chronic HIV-infected patients showing a rapid or delayed viral rebound. Design: Structured treatment interruption consisted of at least one month of discontinuation, followed by highly active antiretroviral therapy (HAART) resumption. Two groups of HIV structured treatment interruption patients were selected on the basis of plasma viral HIV-RNA value (> 30 000 copies/ml, branched DNA): group A (n = 14), patients with a rapid viral rebound (within one month) and group B (n = 6), patients with a delayed or no viral rebound (after a minimum of 4 months). Methods: A clinical and immunological follow-up was performed at HAART suspension (t 0), one month from suspension (t 1), at HAART resumption (t 2), and 30 days from resumption (t 3). Results: A sustained viral rebound was observed in group A patients, showing a rapid expansion of circulating CD8 T lymphocytes. In this group, the frequencies of CD8 T cells releasing IFN-γ after mitogen-induced or Gag-specific stimulation were highly increased after HAART discontinuation. Nevertheless, these CD8 T lymphocytes were mainly composed of pre-terminally differentiated cytotoxic T lymphocytes (CTL) expressing a CCR7- CD27+/- CD45RA- phenotype and a reduced amount of perforin. In contrast, group B patients showed no significant changes in immunological parameters during a prolonged drug-free period. Conclusion: These data indicate that monitoring CD8 T cell dynamics during structured treatment interruption could be clinically relevant, and new therapeutic strategies should aim qualitatively to restore CTL effector functions.",
keywords = "CCR7, CD27, CTL, HAART, HIV-1 Gag, Peptides",
author = "Gianpiero D'Offizi and Carla Montesano and Chiara Agrati and Cristiana Gioia and Massimo Amicosante and Simone Topino and Pasquale Narciso and Pucillo, {Leopoldo Paolo} and Giuseppe Ippolito and Fabrizio Poccia",
year = "2002",
month = "12",
day = "6",
doi = "10.1097/00002030-200212060-00008",
language = "English",
volume = "16",
pages = "2431--2438",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "18",

}

TY - JOUR

T1 - Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption

AU - D'Offizi, Gianpiero

AU - Montesano, Carla

AU - Agrati, Chiara

AU - Gioia, Cristiana

AU - Amicosante, Massimo

AU - Topino, Simone

AU - Narciso, Pasquale

AU - Pucillo, Leopoldo Paolo

AU - Ippolito, Giuseppe

AU - Poccia, Fabrizio

PY - 2002/12/6

Y1 - 2002/12/6

N2 - Objective: The influence of structured treatment interruption on effector/memory CD8 T cell dynamics was analysed in chronic HIV-infected patients showing a rapid or delayed viral rebound. Design: Structured treatment interruption consisted of at least one month of discontinuation, followed by highly active antiretroviral therapy (HAART) resumption. Two groups of HIV structured treatment interruption patients were selected on the basis of plasma viral HIV-RNA value (> 30 000 copies/ml, branched DNA): group A (n = 14), patients with a rapid viral rebound (within one month) and group B (n = 6), patients with a delayed or no viral rebound (after a minimum of 4 months). Methods: A clinical and immunological follow-up was performed at HAART suspension (t 0), one month from suspension (t 1), at HAART resumption (t 2), and 30 days from resumption (t 3). Results: A sustained viral rebound was observed in group A patients, showing a rapid expansion of circulating CD8 T lymphocytes. In this group, the frequencies of CD8 T cells releasing IFN-γ after mitogen-induced or Gag-specific stimulation were highly increased after HAART discontinuation. Nevertheless, these CD8 T lymphocytes were mainly composed of pre-terminally differentiated cytotoxic T lymphocytes (CTL) expressing a CCR7- CD27+/- CD45RA- phenotype and a reduced amount of perforin. In contrast, group B patients showed no significant changes in immunological parameters during a prolonged drug-free period. Conclusion: These data indicate that monitoring CD8 T cell dynamics during structured treatment interruption could be clinically relevant, and new therapeutic strategies should aim qualitatively to restore CTL effector functions.

AB - Objective: The influence of structured treatment interruption on effector/memory CD8 T cell dynamics was analysed in chronic HIV-infected patients showing a rapid or delayed viral rebound. Design: Structured treatment interruption consisted of at least one month of discontinuation, followed by highly active antiretroviral therapy (HAART) resumption. Two groups of HIV structured treatment interruption patients were selected on the basis of plasma viral HIV-RNA value (> 30 000 copies/ml, branched DNA): group A (n = 14), patients with a rapid viral rebound (within one month) and group B (n = 6), patients with a delayed or no viral rebound (after a minimum of 4 months). Methods: A clinical and immunological follow-up was performed at HAART suspension (t 0), one month from suspension (t 1), at HAART resumption (t 2), and 30 days from resumption (t 3). Results: A sustained viral rebound was observed in group A patients, showing a rapid expansion of circulating CD8 T lymphocytes. In this group, the frequencies of CD8 T cells releasing IFN-γ after mitogen-induced or Gag-specific stimulation were highly increased after HAART discontinuation. Nevertheless, these CD8 T lymphocytes were mainly composed of pre-terminally differentiated cytotoxic T lymphocytes (CTL) expressing a CCR7- CD27+/- CD45RA- phenotype and a reduced amount of perforin. In contrast, group B patients showed no significant changes in immunological parameters during a prolonged drug-free period. Conclusion: These data indicate that monitoring CD8 T cell dynamics during structured treatment interruption could be clinically relevant, and new therapeutic strategies should aim qualitatively to restore CTL effector functions.

KW - CCR7

KW - CD27

KW - CTL

KW - HAART

KW - HIV-1 Gag

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=0037032905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037032905&partnerID=8YFLogxK

U2 - 10.1097/00002030-200212060-00008

DO - 10.1097/00002030-200212060-00008

M3 - Article

C2 - 12461417

AN - SCOPUS:0037032905

VL - 16

SP - 2431

EP - 2438

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 18

ER -